Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 694 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Blood test could tailor treatment after surgery July 14, 2021 How Receiving My Own Cancer Diagnosis Changed My Perspective on Caring... August 25, 2020 Innovative cancer spinouts: 3 new projects get green light August 13, 2021 More than 65,000 people are left waiting to find out if... May 8, 2022 Load more HOT NEWS FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years... Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will... ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma
